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Abstract
The German Commission for the Investigation of Health Hazards of Chemical Com-
pounds in the Work Area has re-evaluated furan [110-00‑9]. All toxicity endpoints
have been considered and publications are described in detail.
Genotoxicity data show only a secondary genotoxic effect at high doses and no effect
at low doses.Therefore, furan is classified as a primary non-genotoxic carcinogen. As
a maximum concentration at the workplace (MAK value) can be derived from avail-
able studies, furan was reclassified from Category 2 into Category 4 for carcinogens.
There are no long-term inhalation studies available to derive a MAK value. In
a 13-week study with rats, subcapsular inflammation and apoptosis in the liver of
unclear relevance for humans were observed at 0.12 mg/kg body weight/day with
a NOAEL of 0.03 mg/kg body weight/day. These may be adaptive effects and were
not observed in a two‐year study or its interim investigations. A physiologically
based pharmacokinetic model predicted the burden in human livers to be about
three-fold lower compared with rats. The NOAEL of 0.03 mg/kg body weight/day
was scaled to a concentration at the workplace and a MAK value of 0.02 ml/m3 was
derived, also taking into account the lower liver dose in humans.
The MAK value was derived from a systemic NOAEL; therefore, furan is classified
in Peak Limitation Category II with the default excursion factor of 2 as sufficient
toxicokinetic data are not available, especially for the reactive metabolite
cis-2-butene‑1,4‑dial.
Model calculations show that dermal absorption would contribute substantially to
the systemic toxicity and furan continues to be designated with an “H”.
Because there are no studies on developmental toxicity, furan is assigned to Preg-
nancy Risk Group D.
There are no data on sensitization.
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MAK value (2016) 0.02 ml/m3 ≙ 0.056 mg/m3
Peak limitation (2016) Category II, excursion factor 2
Absorption through the skin (2005) H
Sensitization –
Carcinogenicity (2016) Category 4
Prenatal toxicity (2016) Pregnancy Risk Group D
Germ cell mutagenicity –
BAT value –
Molar mass 68.08 g/mol
Melting point −85.6 ℃ (ECHA 2015)
Boiling point at 1013 hPa 31.5 ℃ (ECHA 2015)
Density at 20 ℃ 0.95 g/cm3 (ECHA 2015)
Vapour pressure at 25 ℃ 798 or 860 hPa (ECHA 2015)
log KOW 1.34 (ECHA 2015)
Solubility at 25 ℃ 10 g/l water (ECHA 2015)
1 ml/m3 (ppm) ≙ 2.825 mg/m3 1 mg/m3 ≙ 0.354 ml/m3 (ppm)
Documentation for furan was published in 2006 (english translation Hartwig and MAK Commission 2018). Furan
was designated with an “H” (for substances which can be absorbed through the skin in toxicologically relevant
amounts) and classified in Carcinogen Category 2 after two‐year oral studies found that furan induced liver adeno-
mas and carcinomas in rats and mice and bile duct carcinomas in rats at the lowest dose tested and above. In the
meantime, studies have become available that established doses without effects. Therefore, the studies have been
reviewed to derive a MAK value.
Furan can be found in heat-processed foods, for example preserved meat and vegetables, vegetable juices, soups,
bread and brewed coffee. The WHO reported that Europeans have an average daily intake of 0.27–1.17 µg/kg body
weight, but the intake may be as high as 2.2 µg/kg body weight if, for example, coffee is consumed in large quantities
(Churchwell et al. 2015).
1 Toxic Effects and Mode of Action
Data published since the 2006 documentation (Hartwig and MAK Commission 2018) confirmed the previously
described mode of action for furan. In rats and mice, oral doses of furan induced carcinogenicity primarily in
the liver and secondary genotoxicity occurred only at cytotoxic concentrations. Apoptosis of hepatocytes was
observed when gavage doses of 0.12 mg/kg body weight and day and above were administered to F344 rats for
13 weeks. A two‐year study with male F344 rats reported cholangiofibrosis in 76% of the animals at gavage doses
of 0.2 mg/kg body weight and day and above; 1 of 100 animals was affected at the dose of 0.092 mg/kg body
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weight and day. When mice were gavaged with furan for 13 weeks, lesions in the liver lobules were observed at
0.5 mg/kg body weight and day and above. Furan is metabolized in the liver mainly by cytochrome P450 (CYP) 2E1.
cis-2-Butene‑1,4‑dial is formed as a reactive metabolite and contributes to the hepatotoxicity only after exposure
to furan at high doses. There are no inhalation studies available.
2 Mechanism of Action
The 2006 documentation (Hartwig and MAK Commission 2018) considered the tumour-promoting activity of furan
to be the main cause of its carcinogenicity. This is induced by cytotoxicity, primarily by the uncoupling of ox-
idative phosphorylation (mitochondrial toxicity) and the subsequent reduced formation of adenosine triphosphate
(ATP).The cytotoxicity is probably caused by the metabolite cis-2-butene‑1,4‑dial and leads to apoptosis. Unspecific
reactions cause necrosis at higher doses. Hepatocytes can survive a decrease in ATP of up to 95%; therefore, the
misrepair of DNA breaks or the manifestation of lesions as a result of increased proliferation and the conversion of
liver tissue is assumed to be an additional effect.
Since the 2006 documentation new studies have been carried out that are described in detail below (see also Table 1).
2.1 Hepatotoxicity
Epigenetic changes in the liver that may have impaired the cell cycle control were observed at 4.4 mg/kg body
weight and day and above in F344 rats given gavage doses of furan for 26 weeks and at 0.92 mg/kg body weight and
day and above in rats exposed for 1 year (see Table 1). The carcinogenicity was attributed to a non-genotoxic mech-
anism in the form of cytotoxicity, inflammation, oxidative stress, demethylation of the liver DNA and increased cell
proliferation (De Conti et al. 2014).
Rats were administered gavage doses of furan of up to 30 mg/kg body weight and day for periods of 1 day to
3 months to investigate the time-dependent changes in the liver (see Table 1). Depending on the extent of the
damage around the central vein of the liver lobules, a rapid proliferation of hepatocytes was observed, or the
proliferation of ductular cells when the damage extended into the periportal field. The ductular cells extended
into the parenchyma and were accompanied by liver fibroblasts (Hickling et al. 2010 a). They either differentiated
into hepatocytes, with the loss of the associated fibroblasts, or progressed to form tortuous ductular structures
that replaced the parenchyma and led to cholangiofibrosis. The latter was observed mainly in regions of the liver
lobules that had been completely destroyed at the beginning of treatment. The mechanism that determined the
direction of differentiation was unclear. It was assumed to be irreversible disturbance of the repair system of
the hepatocellular stem cells (Hickling et al. 2010 a, b). As the CYP2E1 expression was considerably reduced in
the regenerative hepatocytes at constant levels of furan exposure, these were clearly more resistant, resulting in
reduced compensatory proliferation. However, inflammation was found to persist at the affected sites of the liver
lobes even after termination of the furan treatment; this induced oxidative stress in the surrounding tissue. The
carcinogenicity of furanwas considered to be the result of a combination of effects including cytotoxicity, persistent
indirect damage to the DNA as a result of oxygen radicals, conversion of the DNA damage to fixed mutations by
persistent proliferation and changes in the gene expression associatedwith cell cycle control (Hickling et al. 2010 b).
A study in female B6C3F1 mice that were given oral doses of furan for 3 weeks or 2 years showed that tumours
were not caused by hepatic cytotoxicity alone. The doses of 1 and 2 mg/kg body weight and day induced hepatic
cytotoxicity but did not lead to tumour formation. Hepatotoxicity and compensatory cell proliferation were induced
at doses of 4 and 8 mg/kg body weight and day, which led to foci of altered hepatocytes, hepatocellular adenomas
and, at 8 mg/kg body weight and day, to hepatocellular carcinomas (Moser et al. 2009).
Mechanistic studies in rats that were administered gavage doses of furan for up to 3 months reported changes in
the gene expression patterns at lower doses over time (Cooke et al. 2014; Hickling et al. 2010 b).
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In hepatocellular carcinomas of humans and rodents, the expression of the tumour suppressor genes Cdh1, p16INK4
and Rassf1a was frequently down-regulated by methylation. A study with oral furan doses of up to 4.4 mg/kg body
weight and day that were administered to rats for periods of 13, 26 or 53 weeks reported time and dose-dependent
methylation of p16INK4 and Rassf1a (De Conti et al. 2014).






















examination of liver only, examination of all liver lobes, immunocytochemistry with
3 animals/group, control animals after 1 day, 1 month, 3 months,
pathology
day 7: liver pale with swelling and distortion of the caudate and right anterior liver
lobes, increasing up to days 10 and 12, additionally nodules, on day 20: fusion of the
2 liver lobes in some cases, after 3 months: all liver lobes pale, swollen with nodules and
changes in structure,
histopathology/immunocytology
8 hours: in centrilobular and subcapsular regions of all liver lobules: vacuolation,
chromatin aggregation, karyorrhexis, karyolysis →necrosis and apoptosis,
24 hours: influx of inflammatory cells in the case of subcapsular and centrilobular
necrosis,
3 days: most necrosis, inflammation, fibronectin deposits in centrilobular region resolved,
centrilobular parenchyma is replaced by hepatocytes formed by proliferation, surviving
hepatocytes proliferate, portal regions previously largely destroyed: proliferation of
OV-6-positive ductular hepatocytes,
7 days: proliferating ductular hepatocytes extending into the parenchyma,
12 days: new ductular hepatocytes show typical and atypical differentiations, typical
differentiation in portal regions in continuity with hepatic plates, distinct boundary
between cells without bile duct markers OV‑6 and BD1 and Cx43, atypical differentiations
into intestinal cells in regions that had largely been destroyed,
20 days: proliferating ductular hepatocytes replace most of the parenchyma in destroyed
areas of the right and caudate lobes of the liver,
> 20 days to 3 months (including 3 months with 1‑month recovery period): sites of
cholangiofibrosis expand accompanied by chronic inflammatory infiltrates, density of




















examination of liver only, immunohistochemistry with 3 animals/group,
histopathology: see Hickling et al. 2010 a,
CYP2E1: induced following acute toxicity, normal on day 3 and thereafter,
marker for cell proliferation and DNA damage: wild type p53, cdk‑1 (for mitosis), mdm‑2,
phospho-c-jun apparent in surviving hepatocytes after acute exposure, 8‑oxo-dG ↑ in
hepatocytes and ductular hepatocytes,
changes in gene expression after 3‑month exposure and 1‑month recovery period:
HSP 70, GST, IRF‑1, cytochrome b558 for cellular/oxidative stress; for example cyclin E,
annexin II, c‑myc for cell proliferation; TB-10, mANT for apoptosis; carbonic anhydrase II,
TB-10 for tumour progression; cutaneous fatty acid-binding protein S‑100 for metastases
Hickling et al.
2010 b
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scope of examinations: body weights, organ weights, histopathology of prostate
gland, testes, epididymis, seminal vesicles, pituitary gland; serum and intratesticular
testosterone levels; serum LH and FSH levels; 17-OHase, 3‑beta-HSD and 17-beta-HSD
activities, mRNA expression levels of the LH receptor and Tspo,
0.03 mg/kg body weight and above: StAR ↑;
2 mg/kg body weight and above: serum testosterone level ↑, serum LH ↓;
8 mg/kg body weight: intratesticular testosterone level ↑, 25% decrease in serum LH,















examination of liver only
scope of examinations: change in the status of global DNA methylation, promoter
methylation, expression of tumour suppressor genes, expression of chromatin-modifying
genes,
13 weeks: 4.4 mg/kg body weight: Dnmt3b ↓,
26 weeks: trimethylated histones dose-dependently ↓ (H3K9 and H4K20),
4.4 mg/kg body weight: 4/5 animals: methylated p16INK4 ↓, 5/6 animals: methylated
Rassf1a, Dnmt3b ↓,
1 year: trimethylated histones dose-dependently ↓ (H3K9 35%, H4K20 36%), histone
acetyltransferases dose-dependently ↓ (Ep300 and Kat2a),
0.92 mg/kg body weight: DNA methylation 30%, 36% and 49% ↓, dose-dependent
hypermethylation of tumour suppressor gene p16INK4a;
2.0 mg/kg body weight: dose-dependent hypermethylation of tumour suppressor gene
Rassf1a;
4.4 mg/kg body weight: Dnmt3a ↓, Dnmt3b ↓, H3K9ac 45% ↓, H3K56ac 32% ↓, histone-
modifying genes Prdm2 and Suv39h1 and Suv4-20h2 and histone methyltransferases
Ehmt2 ↓,
no changes in Cdh1, Dnmt1, trimethylated histones H3K4, H3K27
de Conti et al.
2014
BrdU: 5‑bromo-2′-deoxyuridine; Cx32: connexin 32; FSH: follicle-stimulating hormone; 3‑beta-HSD: 3‑beta-hydroxysteroid dehydrogenase;
17-beta-HSD: 17-beta-hydroxysteroid dehydrogenase; LH: luteinizing hormone; LI: labelling index; 17-OHase: 17-hydroxylase, C17,20-lyase; OV-6:
specific antibody for the identification of hepatic or ductular precursor cells; SPF: specific pathogen free; StAR: steroidogenic acute regulatory
protein; Tspo: translocator protein
2.2 Genotoxicity
Recent studies likewise showed that the carcinogenicity of furan was not caused by primary genotoxic effects
in vivo (Carthew et al. 2010; Chen et al. 2010; Ding et al. 2012; Durling et al. 2007). As cis-2-butene‑1,4‑dial did
not bind to DNA in vivo (rats), furan is not thought to have a genotoxic mechanism of action (Churchwell et al.
2015). However, some studies reported (reversible) changes in gene expression governing cell cycle control and
apoptosis that were caused by furan after oral treatment of rats for 4 or 13 weeks (Chen et al. 2010, 2012). In mice, an
increase in polyploid cells and DNA repair genes was observed at the highest dose tested of 15 mg/kg body weight
and day (Cordelli et al. 2010). Oxidative stress, which was accompanied by inflammation, cell proliferation and
cytotoxicity, was regarded as having caused the effects (Ding et al. 2012); they were not associated with a change
in DNA methylation (Chen et al. 2010; Cordelli et al. 2010). The genes that were activated among those that play
an important role in cytotoxicity and proliferation were stress-activated protein kinase (SAPK) and death receptor
(DR5, TNF-alpha), extracellular signal-regulated kinases (ERKs) and TNF-alpha and the genes NF-kappaB and c‑Jun,
which are relevant for liver regeneration. NRF2 , the master gene for oxidative stress and chronic inflammation, was
activated in particular (Jackson et al. 2014). The mitochondria are regarded as a critical target; their energy supply
was impaired by the irreversible uncoupling of oxidative phosphorylation caused by furan and ATP depletion
(WHO 2011). Some proteins lost their function as a result of covalent bindings and misfolding (Moro et al. 2012).
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2.3 Summary
An individual mechanism that could be responsible for tumourigenicity cannot be determined from the data. Furan
exhibited a high level of cytotoxicity.This is presumably caused by cis-2-butene‑1,4‑dial, which is formed by CYP2E1
during metabolism. cis-2-Butene‑1,4‑dial is a very reactive substance that binds to glutathione (GSH), amino acids
or DNA in vitro, but has not been demonstrated in vivo, and can lead to DNA cross-links. Furan induces changes
in gene expression, some of them irreversible, as well as cytotoxicity, oxidative stress and proliferation. Low oral
doses of furan did not cause genotoxic effects, whereas secondary genotoxicity was observed after administration
of high doses. In addition, uncoupling of oxidative phosphorylation and ATP depletion in the mitochondria were
reported. Furan induces CYP2E1 and hepatocellular damage around the central vein, which is followed by apoptosis.
If the damage is slight, tissue regeneration originates from the hepatocytes; this tissue is characterized by a much
lower level of CYP2E1 expression resulting in the formation of a smaller amount of cis-2-butene‑1,4‑dial. If the
areas damaged by high doses of furan extend into the periportal field, which contains ductular cells, hepatocytes
and severely proliferating ductular cells cause tissue regeneration. Intestinal cells may also be formed in the liver
lobule. Medium-term or long-term administration of furan induces continuous tissue proliferation, which in turn
causes cholangiofibrosis resulting in cholangiocarcinomas and hepatocellular carcinomas.
Inhalation studies and thus investigations of local toxicity in the respiratory tract were not carried out.
3 Toxicokinetics and Metabolism
3.1 Absorption, distribution, elimination
The retention of inhaled furan in dogs was greater than 90% (Hartwig and MAK Commission 2018).
After the administration of single gavage doses of 14C‑labelled furan, 14% of the radioactivity was exhaled as un-
changed furan and 26% as CO2, 20% of the radioactivity was found in the urine and another 22%was eliminated in the
faeces within the first 24 hours. After 24 hours, 68% of the 19% that remained in the body (13% of the administered
dose) was detected in the liver, bound to macromolecules (Hartwig and MAK Commission 2018).
Fischer 344 rats were gavaged with a furan dose of 0.92 mg/kg body weight and blood samples were taken after 15,
30, 45, 60 and 90 minutes and after 2, 3, 4, 5 and 6 hours to investigate the toxicokinetics of the substance in serum
and liver. The maximum furan concentration in the blood of 63 ± 17 nM was obtained within the first 15 minutes
following administration; the concentration then decreased with a half-life of 1.3 hours. The maximum furan con-
centration in the liver of 547 ± 993 pmol/g tissue was determined 30 minutes after administration of the substance.
It was highly variable and dependent on the time that had passed since administration and the localization of the
liver lobule that was investigated. The relative standard deviation of the furan concentration between the liver lob-
ules was 65%; the same liver lobule was examined from each of the 4 animals. There was a biphasic decrease in the
concentration in the liver with half-lives of 0.55 and 0.62 hours. Furan was no longer detected in the liver or blood
8 hours after administration. The area under the concentration-time curve that was extrapolated to infinity was
772 pmol/g × hour for the liver and 139 nmol/l × hour for the blood. At all sampling times, the furan concentration
in the liver was greater than that in the blood with a mean ratio of about 6.2 (Churchwell et al. 2015).
As the oral route of administration was used in this study, furan first entered the liver and then the systemic
blood. The liver was thus exposed to a higher concentration of furan than the blood. This does not conflict with the
assessment that after inhalation the concentration in the blood is about 10 times as high as that in the liver and the
blood flow in the liver is the rate-limiting step (Churchwell et al. 2015; Kedderis et al. 1993).
Fluxes of 759, 62 and 101 µg/cm2 and hour were calculated for a saturated aqueous solution using the models
of Fiserova-Bergerova et al. (1990), Guy and Potts (1993) and Wilschut et al. (1995), respectively. Assuming the
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Oxidation by CYP2E1 to form cis-2-butene‑1,4‑dial, which binds primarily to thiols, amino groups or amino acids,
is the first step in the metabolism of furan. In vitro studies demonstrated a similar metabolic pathway for humans,
rats and mice. According to a physiologically based pharmacokinetic (PBPK) model, the burden per kg body weight
caused by furan and the exposure to the reactive metabolite cis-2-butene‑1,4‑dial in the liver was 3 and 10 times
lower in humans than that in rats and mice, respectively, after exposure to the same external furan concentration
of 10 ml/m3 (Hartwig and MAK Commission 2018; Kedderis and Held 1996).
3.2.2 Rats
Furan is oxidized by CYP to form cis-2-butene‑1,4‑dial. Studies found the following metabolites in the urine of rats
treated with furan: a monoglutathione-butenedial reaction product, N -[4-carboxy-4-(3-mercapto‑1H -pyrrol-1-yl)-
1-oxobutyl]-L-cysteinylglycine cyclic sulfide, R-2-acetylamino-6-(2,5-dihydro-2-oxo‑1H -pyrrol-1-yl)-1-hexanoic
acid, N -acetyl-S-[1-(5-acetylamino-5-carboxypentyl)-1H -pyrrol-3-yl]-L-cysteine and its sulfoxide. To investigate
the quantitative course of metabolism, the metabolites were quantified in the 24-hour urine of male F344
rats after single gavage doses of ring-labelled furan of 8 or 40 mg/kg body weight. As only trace amounts of
N -acetyl-S-[1-(5-acetylamino-5-carboxypentyl)-1H -pyrrol-3-yl]-L-cysteine (“end product” of the reaction of
2‑butene‑1,4‑dial with GSH) was detected in the urine, two main in vivo pathways were identified: the subsequent
binding to nucleophilic macromolecules or the direct binding of 2‑butene‑1,4‑dial to macromolecules (Lu et al.
2009).
Studies with rat hepatocytes showed that the metabolite cis-2-butene‑1,4‑dial reacted with glutathione to form
2‑(S-glutathionyl)succinaldehyde, which forms pyrrole cross-links with cellular amines such as lysine and glu-
tamine and also with ornithine, putrescine and spermidine. Mercapturic acid derivatives of the spermidine cross-
links were detected in the urine of rats treated with furan. The authors concluded that this metabolic pathway
occurs in vivo (Peterson et al. 2011).
A single [3,4-13C] furan dose of 5 mg/kg body weight was administered to 3 bile duct-cannulated rats and
the metabolites were recovered in the bile in 30-minute fractions over a period of 4 hours and analysed. The
cyclic monoglutathione conjugate of cis-2-butene‑1,4‑dial, an N -acetylcysteine-N -acetyllysine conjugate and
a cysteinylglycine-glutathione conjugate were identified as the main metabolites. All these metabolites had
previously been detected in the urine of exposed rats (Hamberger et al. 2010).
4 Effects in Humans
There are no data available.
5 Animal Experiments and in vitro Studies
5.1 Acute toxicity
There are no new data available.
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5.2 Subacute, subchronic and chronic toxicity
5.2.1 Inhalation
There are no new data available. Earlier studies that were included in the 2006 documentation (Hartwig and MAK
Commission 2018) were documented inadequately and have not been included in the evaluation.
5.2.2 Oral administration
The liver is the main target organ of furan. A 2‐year study with rats and mice reported a dose-dependent increase
in tumours in the liver at the low dose and above (see Section 5.7; Hartwig and MAK Commission 2018).
Studies with repeated oral administration of furan that were not included in the 2006 documentation (Hartwig and
MAK Commission 2018) are shown in Table 2 to 6.
Initially, low gavage doses of furan induced only hepatotoxicity in rats and mice. A NOAEL (no observed adverse
effect level) of 0.03 mg/kg body weight and day was determined in F344 rats after 13-week administration; at
0.12 mg/kg body weight and day and above, slight histopathological changes were observed in the caudate lobe
of the liver that increased in severity with the dose. In addition, apoptosis of hepatocytes, Kupffer cells with yel-
low pigment deposits and foci of subcapsular inflammatory cells were found. Up to 8 mg/kg body weight and day,
substance-induced findings were not observed in any other organ, whereas the findings in the liver increased in
a dose-dependent manner. The first effects may appear in the caudate lobe because the caudate lobe is located clos-
est to the stomach and therefore diffusion into liver tissue may have taken place. The animals for the study were
obtained from Charles River, Quebec (see Tables 2 and 3; Gill et al. 2010).
A NOAEL of 0.092 mg/kg body weight and day was determined by a study with two‐year gavage administration of
furan to male F344 rats; at 0.2 mg/kg body weight and above, cholangiofibrosis was observed in 76% of the animals
(see Table 6). The interim examinations after 9 and 15 months showed that the NOAEL decreased with an increase
in time (see Tables 4 and 5). The hepatotoxicity increased in a dose-dependent manner up to the highest dose tested
of 2 mg/kg body weight and day; cholangiocarcinomas were not observed (FDA 2015). Meanwhile the study by FDA
(2015) has been published (Von Tungeln et al. 2017).
It is unclear why the sensitivity of hepatocytes and bile duct cells differed in the 13-week and two‐year studies.
Slight genetic differences may have been responsible because the animals of the 13-week study were obtained from
Charles River in Quebec, Canada, and the animals of the two‐year study were bred by the National Center for
Toxicological Research in the United States.
Gavage studies that were carried out for 3 weeks, 13 weeks and 2 years are available for mice; they confirmed that
the liver is the most sensitive target organ. After 13-week administration of furan, lesions in the liver lobule were
observed at 0.5 mg/kg body weight and day and above; the NOAEL was 0.12 mg/kg body weight and day. In the
two‐year study, histopathological findings were observed only in the liver; subcapsular inflammation was found
at the low dose of 0.5 mg/kg body weight and day (see also section 5.7; Gill et al. 2011; Moser et al. 2009).
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0, 0.03, 0.12, 0.5, 2.0, 8.0 mg/kg
body weight and day,
5 days/week,
in corn oil, purity: > 99%,
gavage
0.03 mg/kg body weight: NOAEL for hepatotoxicity;
0.12 mg/kg body weight and above: changes in the caudate lobe
of the liver (see Table 3), hepatocyte apoptosis (♂), Kupffer cells with
yellow pigment deposits (♂), foci of subcapsular inflammatory cells;
biochemical parameters: T4 (♂) ↑;
0.5 mg/kg body weight and above: in all animals, changes in the
caudate lobe of the liver, similar changes in the left liver lobe; cell
layer thickness increased with hepatocytes with cytomegaly and
karyomegaly and dark basophilic cytoplasm, hepatocyte apoptosis,
Kupffer cells with yellow pigment deposits ↑ (♀);
biochemical parameters: triglycerides (♂) ↓, number of platelets (♀) ↑;
2.0 mg/kg body weight and above: subcapsular and periportal
proliferation of oval cells, bile duct hyperplasia, infiltrates: inflammatory
cells, fibrosis;
biochemical parameters: ALT (♀) ↓, ALP (♂) ↑, albumin (♀) ↑, amylase
(♂) ↓, globulin (♂) ↓, glucose ↓, total protein (♀) ↑, triglycerides (♀) ↓,
phosphorus (♀) ↑, T3 (♀) ↑;
8.0 mg/kg body weight: 14%–22% increase in absolute liver weights,
nodules in liver (mainly in the caudate and left lateral liver lobes),
histopathological changes in all liver lobes, biliary epithelial and oval
cell hyperplasia, cholangiofibrosis instead of hepatic parenchyma;
biochemical parameters: ALT ↓, albumin ↑, cholesterol (♂) ↑, number of
platelets ↑, %CD4+CD8+ (♂) ↓, %CD4+CD8− (♂) ↑ (♀ also trend) (possibly
thymus toxicity);
scope of examinations: feed consumption, body and organ weights;
in all dose groups: histopathology of liver, kidneys, thymus, spleen;
only control and highest dose group: histopathology of stomach,
thyroid gland, adrenal glands, pancreas, testes, epididymis, prostate
gland, seminal vesicles, ovaries, uterus and vagina; only organ weight
determined: heart; paired organs weighed separately; end of study:










9 (n = 20) and 15 (n = 10)
months,
0 (n = 190), 0.02 (n = 180),
0.044 (n = 130), 0.092 (n = 130),
0.2, 0.44, 0.92, 2 mg/kg body
weight and day, 5 days/week,
in corn oil, purity: 99.5%,
gavage
2 years,
for findings in the liver see Table 4 (9 months), Table 5 (15 months),
Table 6 (2 years),
0.092 mg/kg body weight (n = 100): NOAEL;
0.2 mg/kg body weight and above (n = 50): hepatotoxicity; after
2 years: cholangiofibrosis in 76% of the animals (see Table 6);
2 mg/kg body weight (n = 50): hyperplasia of myeloid cells in the
bone marrow (43%**, controls: 24%), cataract in the eye (13%**, controls:
1%), oedema in the forestomach (31%*, controls: 18%), hyperplasia
in the epithelium of the forestomach (44%*, controls: 28%), chronic
inflammation of the forestomach (40%*, controls: 22%), ulcer in the
forestomach (19%*, controls: 9%), hyperplasia in the transitional
epithelium of the kidneys (38%**, controls: 18%), sinus dilation in
the pancreatic lymph node (12%**, controls: 0%), hyperplasia in the
parathyroid gland (38%*, controls: 26%), cysts on the skin (12%**,
controls: 3%), follicular cysts in the thyroid gland (14%*, controls: 5%),
mineralization in testis (6%*, controls: 1%)
FDA 2015
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(14%, ♂: 52%) and
because both sexes
generally react in the
same way
3 weeks,
0, 0.5, 1, 2, 4, 8 mg/kg body




end of study: separate and histopathological examination of liver lobes
only;
0.5 mg/kg body weight and above: hepatotoxicity (degeneration
of hepatic parenchyma, inflammation or subcapsular necrosis and
inflammation in hepatocytes on an area with contact with forestomach),
trend towards increased ALT, trend towards increased cell proliferation
(BrdU) and labelling index;
1 mg/kg body weight and above: ALT ↑, incidence of mitotic figures
in hepatocytes ↑, statistically significant hepatotoxicity;
2 mg/kg body weight and above: positive trend towards increased
labelling index;
4 mg/kg bodyweight and above: absolute and relative liver weights ↑;












0, 0.03, 0.12, 0.5, 2.0, 8.0 mg/kg
body weight and day,
5 days/week,
in corn oil, purity: > 99%,
gavage
0.12 mg/kg body weight: NOAEL for hepatotoxicity, phosphorus
(♂) ↑;
0.5 mg/kg body weight and above: blood urea ↓, (subcapsular) lesions
in the caudate liver lobe;
2 mg/kg body weight and above: serum amylase (♀) ↓,
caudate liver lobes: hepatocyte apoptosis, Kupffer cells with yellow
pigment deposits, oval cell hyperplasia, inflammatory infiltrates,
border of enlarged hepatocytes with basophilic cytoplasm and nucleoli
between parenchyma and subcapsular lesions,
left lobe: subcapsular hepatocyte apoptosis and Kupffer cells with
pigment deposits, inflammatory infiltrates,
right lobe: similar findings in 1 ♂ and 1 ♀;
8 mg/kg body weight: 14% increase in absolute and relative liver
weights (♀), ALT ↑, uric acid (♂) ↑, findings in the right liver lobe in
2 ♂ and 2 ♀, apoptotic hepatocytes in the parenchyma (♀), bile duct
hyperplasia;
scope of examinations: feed consumption, body and organ
weights; histopathology: in all dose groups: individual liver lobules;
histopathology of control and high dose groups only: kidneys, spleen,
lungs, thymus, stomach, adrenal glands, testes, ovaries; histology of
uterus, mammary glands, seminal vesicles, thyroid gland, lungs, pan-
creas, heart, brain, prostate gland, epididymis, colon, gallbladder, small
and large intestines; paired organs weighed separately; end of study:









(14%, ♂: 52%) and
because both sexes
generally react in the
same way
2 years,
0, 0.5 (n = 100), 1 (n = 75), 2,





only liver lobes examined histopathologically;
0.5 mg/kg body weight and above: hepatotoxicity (subcapsular
inflammation);
1 mg/kg body weight and above: statistically significant cytotoxicity
in the liver;
4 mg/kg body weight and above: relative liver weights ↑, foci of
changes in hepatocytes, hepatocellular adenomas, hepatocellular
adenomas plus carcinomas, number of nodules in hepatocytes ↑; see
also section 5.7
8 mg/kg body weight: hepatocellular carcinomas, multiplicity of
microtumours ↑, latency period up to tumour ↓
Moser et al.
2009
* p < 0.05; ** p < 0.01
ALT: alanine aminotransferase; ALP: alkaline phosphatase; BrdU: 5‑bromo-2′-deoxyuridine; SPF: specific pathogen free; T3: Triiodothyronine;
T4: thyroxine
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Tab. 3 Findings in the liver of F344 rats 13 weeks after gavage administration of furan (5 days/week) (Gill et al. 2010)
Dose (mg/kg body weight and day)
























































































Tab. 4 Findings in the liver 9 months after oral administration of furan (5 days/week) in male F344 rats (FDA 2015)
Dose (mg/kg body weight and day)
0 0.02 0.044 0.092 0.2  0.44  0.92  2
cholangiofibrosis 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%)  6/20** (30%) 17/20** (85%) 19/20** (95%)
mixed cell foci 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%) 1/20 (5%)  0/20 (0%)  1/20 (5%)  5/20* (25%)
biliary duct hyperplasia 1/20 (5%) 1/20 (5%) 0/20 (0%) 1/20 (5%) 0/20 (0%)  0/20 (0%)  6/20* (30%) 19/20** (95%)
subcapsular biliary duct
hyperplasia
0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%) 1/20 (5%) 12/20** (60%) 19/20** (95%) 20/20** (100%)
oval cell hyperplasia 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%)  0/20 (0%)  1/20 (5%) 16/20** (80%)
hepatocyte hypertrophy 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%) 1/20 (5%)  0/20 (0%)  2/20** (10%) 12/20** (60%)
cytoplasmic changes in
the periportal field
0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%)  0/20 (0%)  7/20* (35%) 19/20** (95%)
subcapsular fibrosis 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%) 3/20 (15%) 14/20** (70%) 20/20** (100%) 20/20** (100%)
subcapsular chronic
inflammation
0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%) 2/20 (10%) 14/20** (70%) 20/20** (100%) 20/20** (100%)
subcapsular pigmentation 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%) 2/20 (10%) 14/20** (70%) 20/20** (100%) 20/20** (100%)
* p < 0.05; ** p ≤ 0.01
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Tab. 5 Findings in the liver 15 months after oral administration of furan (5 days/week) in male F344 rats (FDA 2015)
Dose (mg/kg body weight and day)
0 0.02 0.044 0.092 0.2  0.44  0.92 2






































cytoplasmic changes in the
periportal field


























* p < 0.05; ** p ≤ 0.01
Tab. 6 Findings in the liver 2 months after oral administration of furan (5 days/week) in male F344 rats (FDA 2015)
Dose (mg/kg body weight and day)
 0  0.02  0.044  0.092  0.2  0.44  0.92  2
cholangio-
fibrosis
 0/149 (0%)  0/150 (0%)  0/99 (0%)  1/100 (1%) 38/50** (76%) 49/49** (100%) 47/50** (94%) 49/49** (80%)
mixed cell foci  7/149 (5%)  7/150 (5%)  6/99 (6%)  3/100 (3%)  5/50 (10%)  3/49 (6%)  6/50 (12%) 13/49** (27%)
basophilic foci 28/149 (19%) 16/150 (11%) 19/99 (19%) 18/100 (18%) 11/50 (22%) 13/49 (27%) 10/50 (20%) 13/49** (27%)
biliary duct
hyperplasia
89/149 (60%) 86/150 (57%) 59/99 (60%) 56/100 (56%) 29/50 (58%) 25/49 (51%) 32/50 (64%) 43/49** (88%)
oval cell
hyperplasia
14/149 (9%) 15/150 (10%) 10/99 (10%)  8/100 (8%)  7/50 (14%)  6/49 (12%) 14/50** (28%) 33/49** (67%)
regenerative
hyperplasia
 0/149 (0%)  1/150 (1%)  1/99 (1%)  2/100 (2%)  1/50 (2%)  1/49 (2%)  7/50** (14%) 12/49** (25%)
cytoplasmic
vacuolation
23/149 (15%) 23/150 (15%) 14/99 (14%) 19/100 (19%) 12/50 (24%) 18/49** (37%) 23/50** (46%) 37/49** (76%)
* p < 0.05; ** p ≤ 0.01
5.2.3 Dermal application
There are no new data available.
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5.3 Local effects on skin and mucous membranes
There are no new data available.
5.4 Allergenic effects
There are no new data available.
5.5 Reproductive and developmental toxicity
There are still no studies specifically of effects on fertility or development.
Oral 90-day studies did not demonstrate effects on the reproductive organs of B6C3F1 mice (Gill et al. 2011) or F344
rats (Gill et al. 2010) up to 8 mg/kg body weight and day (see Table 2).
Another 90-day study with gavage administration reported decreases in absolute and relative prostate weights and
seminal vesicle weights in male Wistar rats at 8 mg/kg body weight and day, whereas the weights of the testis
and epididymis were not affected. The concentration of luteinizing hormone in serum was reduced, as was the
concentration of testosterone at 2 mg/kg body weight and day and above. A dose-dependent increase in apoptosis




Studies of in vitro genotoxicity are shown in Table 7.
5.6.1.1 Furan
Furan did not induce gene mutations in Salmonella typhimurium either with or without the addition of metabolic
activation (Mortelmans et al. 1986), unscheduled DNA repair in rat or mouse hepatocytes (Wilson et al. 1992) or
DNA strand breaks in mouse lymphoma cells (Kellert et al. 2008).
The results for the induction of sister chromatid exchange were positive in some cases, but they were not regarded
as conclusive by the National Toxicology Program (NTP 1993).
In a chromosomal aberration test in CHO (Chinese hamster ovary) cells, aberrations were induced both with and
without the addition of metabolic activation at 100 µM and above (NTP 1993); in another chromosomal aberration
study, furan was shown to have clastogenic activity only after metabolic activation and the addition of nicotinamide
adenine dinucleotide phosphate at 12 500 µg/ml and above (Stich et al. 1981).
In micronucleus tests in human lymphocytes or mouse lymphoma cells, treatment with furan up to cytotoxic
concentrations did not induce micronuclei either with or without the addition of metabolic activation (Durling
et al. 2007) or without metabolic activation (Kellert et al. 2008).
Furan did not cause changes at the tk+/− locus in mouse lymphoma cells without metabolic activation (Kellert et al.
2008; McGregor et al. 1988; NTP 1993). The evaluation made no distinction between large and small colonies.
5.6.1.2 Metabolite cis-2-butene-1,4-dial
In a mutagenicity test with Salmonella typhimurium, cis-2-butene‑1,4‑dial did not inducemutations, with the excep-
tion of positive results obtained in the aldehyde-sensitive strain TA104 (Peterson et al. 2000). cis-2-Butene‑1,4‑dial
was incubated with Salmonella typhimurium TA104 for 30 minutes, the DNA was isolated and, after preparation,
The MAK Collection for Occupational Health and Safety 2020, Vol 5, No 2 13
MAK Value Documentations – Furan
analysed for DNA adducts by mass spectroscopy. A dose-dependent increase in deoxycytidine and deoxyadenosine
adducts was observed (Byrns et al. 2006; Peterson 2006).
In a comet assay in mouse lymphoma cells, DNA strand breaks and DNA cross-links were detected at 25 and 100 µM
and above, respectively (Kellert et al. 2008). cis-2-Butene‑1,4‑dial did not induce micronuclei in mouse lymphoma
cells up to cytotoxic concentrations, but gene mutations were detected at the tk+/− locus at a relative cell growth
of only 30% (Kellert et al. 2008).
In mouse embryonic fibroblasts transgenic for cII , the number of mutations was not increased, but the increase in
the mutation spectrum to transversions (AT→CG) was statistically significant (Terrell et al. 2014).
Tab. 7 Studies of the genotoxicity of furan and the metabolite cis-2-butene-1,4-dial in vitro
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The MAK Collection for Occupational Health and Safety 2020, Vol 5, No 2 14
MAK Value Documentations – Furan
Tab. 7 (continued)
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Tab. 7 (continued)
























































CBMN: cytokinesis-block micronucleus; GSH: glutathione; m. a.: metabolic activation; NADP: nicotinamide adenine dinucleotide phosphate; n. t.:
not tested; PBS: phosphate buffered saline; RTG: relative total growth; SCE: sister chromatid exchange; SMT: Salmonella mutagenicity test; UDS:
unscheduled DNA synthesis
5.6.2 In vivo
In vivo genotoxicity data are shown in Table 8. Data are available only for furan, but not for its metabolite cis-2-
butene‑1,4‑dial.
5.6.2.1 Drosophila
Furan did not induce sex-linked recessive lethal mutations in the SLRL test in Drosophila (IARC 1995).
5.6.2.2 Mammals
14C‑labelled DNA adducts were found in the liver and kidneys of rats given a single gavage dose of furan. The cis-2-
butene‑1,4‑dial metabolite did not form adducts with the bases adenine, cytosine or guanine (Neuwirth et al. 2012).
In mice, single intraperitoneal and gavage doses of furan of up to 350 and 100 mg/kg body weight, respectively, did
not induce either sister chromatid exchange or unscheduled DNA repair (Neuwirth et al. 2012; NTP 1993; Wilson
et al. 1992). The comet assay revealed an increase in DNA damage in the liver of mice and rats after a single gavage
dose of 250 mg/kg body weight or doses of 16 mg/kg body weight and above (Cordelli et al. 2010; Ding et al. 2012),
gavage doses of 2 mg/kg body weight and day for 28 days with a 14-day recovery period (Neuwirth et al. 2012) and
gavage doses of 8 mg/kg body weight and day and above for 8 weeks (McDaniel et al. 2012). However, DNA strand
breaks were not induced in the liver of mice after 4‑week treatment with up to 15 mg/kg body weight and day
(Cordelli et al. 2010) or in the spleen after a single or 4‑week treatment of mice with gavage doses (Leopardi et al.
2010). In rats, no increase in DNA strand breaks was observed either in the bone marrow after a single treatment
(Ding et al. 2012) or in the bone marrow and liver after 5‑day and 28-day treatment, respectively (Neuwirth et al.
2012). In mice, DNA damage was detected by γH2AX staining in the spleen (Leopardi et al. 2010) at 8 mg/kg body
weight and day and above after 4‑week gavage treatment and stimulation of proliferation by concanavalin A;
however, no DNA damage was observed in the liver up to furan doses of 15 mg/kg body weight and day (Cordelli
et al. 2010). The number of DNA cross-links was not increased in the liver or spleen after a single treatment with
doses of up to 15 mg/kg body weight (Cordelli et al. 2010; Leopardi et al. 2010).
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The increase in the number of polyploid cells in the liver of mice was statistically significant after treatment with
gavage doses of up to 15 mg/kg body weight and day for 4 weeks, whereas there was no change in DNAmethylation
(Cordelli et al. 2010).
In the bone marrow of mice, chromosomal aberrations were induced concurrently with cytotoxic effects 36 hours
after a single intraperitoneal injection of 250 mg/kg body weight, but not 17 hours after the administration of
350 mg/kg body weight (NTP 1993). When rats were given gavage doses for 28 days, the incidence of chromosomal
aberrations was increased in splenocytes at 0.5 mg/kg body weight and day and above, whereas in the bone marrow
the induction of chromosomal aberrations or micronuclei was not observed up to 2 mg/kg body weight and day
(Neuwirth et al. 2012).
In splenocytes that were stimulated for proliferation, micronuclei were not induced in mice after a single or 4‑week
treatment with gavage doses of up to 250 mg/kg body weight or 15 mg/kg body weight and day (Leopardi et al. 2010)
or after a single intraperitoneal or subcutaneous injection of 300 or 275 mg/kg body weight (Durling et al. 2007).
Likewise, micronuclei were not detected in the peripheral blood of rats after a single, 1‑week or 8‑week treatment
with gavage doses of up to 16 mg/kg body weight or up to 30 mg/kg body weight and day (Ding et al. 2012; McDaniel
et al. 2012).
In Big Blue rats, gene mutations were not observed in the cII transgene in the liver, in the Hprt gene in the
T lymphocytes of the spleen or in the Pig‑a gene in the peripheral blood up to doses of 30 mg/kg body weight
and day (McDaniel et al. 2012). Likewise, the incidence of gene mutations in the cII transgene in the liver of Big
Blue mice was not increased up to 15 mg/kg body weight and day, but there was a shift in the mutation spectrum.
An increased, but not statistically significant incidence of GC to AT transversions was observed and there was
a (statistically significant) decrease in GC to AT transitions (Terrell et al. 2014). In 60% of liver tumours induced
by furan, there was a shift in the mutation spectrum of the tumours in the oncogene Hras from G to T and G to C
transversions in codon 117; according to the authors, this was a direct genotoxic mechanism (Reynolds et al. 1987).
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Tab. 8 Studies of the genotoxicity of furan in vivo























+ 3,4-14C‑furan dose, analysis by
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examination after 3 hours: effects
due to DNA strand breaks,
alkali-labile sites or DNA repair
intermediates;
100 mg/kg body weight and
above: signs of toxicity;
histopathology: diffuse change
in the parenchyma with areas of
necrosis
Cordelli et al. 2010
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Tab. 8 (continued)
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toxicity; histopathology of the
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(T cell region, B cell region); no
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Tab. 8 (continued)










I: 0, 16 mg/kg body weight,
II: 0, 2, 4, 8, 12, 16 mg/kg
body weight,
gavage,
4× (0, 24, 48, 69 hours)
I: +
II: +
I: examination 1, 3, 6, 8, 16,
24 hours after treatment;






FPGI: 1–3 hours after treatment ↑
II: examination 72 hours after
treatment,
DNA tail length:
8 mg/kg body weight and
above: without pre-treatment ↑
(statistically significant); 4 mg/kg
body weight and above: pre-
treatment with EndoIII: ↑;





cell proliferation (Ki-67): dose-
dependent increase; statistically
significant change in expression
of functional genes responsible
for apoptosis, cell cycle arrest
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with recovery at 2 mg/kg body
weight and day
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Tab. 8 (continued)
Test system Species Dose Result Comments References






10 ♂/group 0–250 mg/kg body weight,
intraperitoneal,
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+ examination 36 hours after
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+ 5 days: CA ↑ at 2 mg/kg body
weight and day,
28 days: CA ↑ at 0.5 mg/kg body
weight and above
28 days + recovery: CA ↑ at
2 mg/kg body weight,













(the first two doses only
8 mg/kg body weight and
day)
– examination 24 hours after last
treatment: serum ALT levels ↑
(statistically significant after 1×,
3‑week and 6‑week treatment),
histopathology: hepatocellular
necrosis with reactive leukocytes
and atypical mitoses after
6‑week treatment (multipolar in
hepatocytes, delayed cell cycle
and non-attached condensed
chromatin); cell proliferation:













+ cII mutation spectrum: GC→AT









60% of furan-induced liver
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or Hras (outside codon 61)












examination 24 hours after last
treatment
McDaniel et al. 2012
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Tab. 8 (continued)




8 weeks – 30 mg/kg body weight and day:































































examination 24 hours after last
treatment,
no cytotoxicity;
no signs of toxicity; histopathol-
ogy of the spleen: changes in the
white pulp (T cell region, B cell


















– no data for cytotoxicity Neuwirth et al. 2012
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Tab. 8 (continued)
Test system Species Dose Result Comments References
I: 0, 50, 75, 90, 110, 125, 150,



























examination 42 hours after last
treatment,
no evidence of dose-response
relationship;
I: 300 or 275 mg/kg body weight:
signs of reduced physical activity;










0, 2, 4, 8, 12, 16 mg/kg body
weight,
gavage,
4× (0, 24, 48, 69 hours)
– examination 3 hours after last
treatment,
12 mg/kg body weight and above:





cell proliferation (Ki-67): dose-
dependent increase; statistically
significant change in expression
of functional genes of apoptosis,
cell cycle arrest and DNA repair
at 2 mg/kg body weight and above
Ding et al. 2012
ALT: alanine aminotransferase; BrdU: 5‑bromo-2′-deoxyuridine; CA: chromosomal aberration; EndoIII: endonuclease III; FPGI:
formamidopyrimidine-DNA glycosylase; RET: reticulocytes; SCE: sister chromatid exchange; SLRL: sex-linked recessive lethal
5.6.3 Summary
In vitro, furan has clastogenic potential and the metabolite cis-2-butene‑1,4‑dial is mutagenic in the aldehyde-
sensitive Salmonella strain TA104. In addition, cis-2-butene‑1,4‑dial forms adducts in vitro with deoxyribonu-
cleotides of guanine, cytosine and adenine. Likewise, mutations that were not observed in spontaneous liver tu-
mours were found in the activated oncogenes of liver tumours induced by furan (Hartwig and MAK Commission
2018).
The following conclusions are drawn on the basis of the new data:
The low boiling point, the selection of the cell line, the absence of suitable activation enzymes (CYP2E1 is not
present in L5178Y cells and has only low activity in routinely induced rat liver S9) or the presence of detoxification
systems all contribute to the inconsistency of the in vitro genotoxicity test results that were obtained with furan.
The reactive furan metabolite, cis-2-butene‑1,4‑dial, is mutagenic in vitro. However, clear evidence of an association
between the metabolism of furan and genotoxicity in the cell is difficult to provide because of the high chemical
reactivity of cis-2-butene‑1,4‑dial. Furan is activated extracellularly in many test systems. As cis-2-butene‑1,4‑dial
reacts rapidly with the protein nucleophiles, it probably does not reach the nuclear DNA.
Most in vivo genotoxicity tests with furan yielded negative results. Tests in Big Blue rats and mice revealed neither
increases in DNA damage in the bone marrow and spleen or micronuclei in the blood and spleen, nor mutations in
the Hprt gene in the spleen, in the Pig‑a gene in the blood or spleen and in the cII transgene in the liver. The comet
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assay revealed DNA damage in the liver as the target organ in rats and mice and a shift in the mutation spectrum
from GC to TA transversions in mice.
The extent of furan metabolism in vitro or in vivo is not known. It is possible that such a small amount of furan is
metabolized that the test systems (even the most sensitive methods) are not sensitive enough to detect a genotoxic
mechanism (Durling et al. 2007).
Only in vitro data are available for the metabolite of furan, cis-2-butene‑1,4‑dial. The data show that for the narrow
concentration range in which the genotoxicity of the substance can be investigated, the contribution of genotoxic
effects of cis-2-butene‑1,4‑dial to the development of the tumours induced by furan cannot be completely excluded.
Concentrations that double the control values in genotoxicity tests are associated with a decrease in plating effi-
ciency, relative growth and survival. The cytotoxicity of cis-2-butene‑1,4‑dial seems to be the predominant factor
for the toxicity and carcinogenicity of furan (Kellert et al. 2008).
Furan induces GC to TA transversions in the cII transgene in the liver and is genotoxic via secondary mechanisms
at cytotoxic concentrations that are accompanied by inflammation and cell proliferation.
5.7 Carcinogenicity
As described in the 2006 documentation (Hartwig and MAK Commission 2018), the NTP carcinogenicity study in
F344 rats yielded cholangiocarcinomas (86%–98%) at the lowest dose tested of 2 mg/kg body weight and day and
above; in addition, hepatocellular adenomas or carcinomas, mononuclear leukaemia and damage to the haematopoi-
etic system were observed at higher doses. Likewise, hepatocellular adenomas or carcinomas and phaeochromocy-
tomas in the adrenal medulla were found in mice at the lowest dose tested of 8 mg/kg body weight and day and
above.
New studies have since been carried out (see Table 9).
An oral two‐year study with female B6C3F1 mice used more animals in the low dose groups for a more precise
determination of the onset of hepatotoxicity; histopathological examination was carried out only in the liver.
Dose-dependent hepatotoxicity was observed at 0.5 mg/kg body weight and day and above. Statistically significant
increases in tumour incidences were observed for hepatocellular adenomas or carcinomas at 4 mg/kg body weight
and day and above and for hepatocellular carcinomas at 8 mg/kg body weight and day (Moser et al. 2009).
As the two‐year gavage study carried out by the NTP (1993) reported that female and male F344 rats reacted with
similar sensitivity, only male animals were used in a new two‐year study with gavage doses of 0.02 to 2 mg/kg
body weight and day. Malignant mesotheliomas were observed in the epididymis or testis with an incidence that
narrowly reached statistical significance only at 2 mg/kg body weight and day. The incidence of mononuclear
leukaemia was increased at 0.2 mg/kg body weight and day and above; however, as the increased incidence was
in the range of the mean and standard deviation of the historical controls of this laboratory, it is not considered
to have been caused by the treatment with furan. A higher number of animals was used in the low dose groups
(150 or 100 per dose) to increase the likelihood of detecting changes at low dose levels. The objective of the study
was to determine the dose–response relationship of cholangiocarcinomas. Cholangiocarcinomas were identified
according to the criteria established by Thoolen et al. (2010). On the basis of these criteria, cholangiocarcinomas
were not observed in male F344 rats. A follow-up examination of 23 livers from the 2 mg/kg group of the NTP study
from 1993 found that only 3 livers had cholangiocarcinomas as defined by the criteria developed by Thoolen et al.
(2010) (NTP (1993): 43/50). A follow-up examination of 6 livers from the 8 mg/kg group of the NTP study from 1993
found that all animals had cholangiocarcinomas as defined by the criteria developed by Thoolen et al. (2010) (FDA
2015). Meanwhile the study by FDA (2015) has been published (Von Tungeln et al. 2017).
The MAK Collection for Occupational Health and Safety 2020, Vol 5, No 2 24
MAK Value Documentations – Furan
Tab. 9 Carcinogenicity studies of furan
Author: Moser et al. 2009
Substance: Furan (purity: 99%)
Species: mouse, B6C3F1, 50 ♀ per group
Administration route: oral
Dose: 0, 0.5 (n = 100), 1 (n = 75), 2, 4, 8 mg/kg body weight and day
Duration: 2 years, 5 days/week
Toxicity: 0.5 mg/kg body weight and day and above: dose-dependent hepatotoxicity
dose (mg/kg body weight and day)
0 0.5 1 2 4 8
surviving animals ♀ 33/50 (66%) 69/100 (69%) 45/75 (60%) 40/50 (81%) 32/50 (64%) 27/50 (54%)
tumours and pre-neoplasms in the liver






15/25 (60%)* 22/22 (100%)*
foci of altered hepato-
cytes
terminal rate












♀  3/25 (12%)  5/55 (9%)  5/36 (14%)  4/31 (13%)  9/25 (36%)* 14/22 (64%)*
* p < 0.05
Author: FDA 2015
Substance: Furan (purity: 99.5%)
Species: rat, F344, 50 ♂/group unless otherwise specified
Administration route: gavage
Dose: 0 (n = 190), 0.02 (n = 180), 0.044 (n = 130), 0.092 (n = 130), 0.2, 0.44, 0.92, 2 mg/kg body weight and day for the detection of
slight effects at a low dose,
interim examination after 9 (n = 20) and 15 (n = 10) months without neoplastic findings
Duration: 2 years, 5 days/week
Toxicity: 0.2 mg/kg body weight and above: dose-dependent hepatotoxicity
dose (mg/kg body weight and day)









16/50 (32%) 13/50 (26%) 12/50 (24%) 08/50 (16%)
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epididymis  6/149 (4%)  8/149 (5%)  1/98 (1%)  2/100 (2%)  0/50 (0%)  2/50 (4%)  2/50 (4%)  5/50 (10%)
testis  5/150 (3%)  7/149 (5%)  1/98 (1%)  1/100 (1%)  0/50 (0%)  2/49 (4%)  2/50 (4%)  4/50 (8%)
epididymis or testis  6/150 (4%)  8/150 (5%)  1/98 (1%)  2/100 (2%)  0/50 (0%)  2/50 (4%)  2/50 (4%)  6/50 (12%)*


















* p < 0.05; ** p < 0.01 (poly‑3 test);
a) historical control animals in this laboratory from 1988–2014: 31/742 (4.2%; 0.0%–6.4%);
b) with mesothelioma of the atrium of the heart;
c) historical control animals in this laboratory from 1988–2014: 348/742 (46.9%; 31.3%–64.6%)
6 Manifesto (MAK value/classification)
There are no inhalation studies available. The critical effect of furan after oral exposure is toxicity, primarily in the
liver of rats and mice and in the bile ducts of rats, which leads to carcinomas after long-term exposure.
Carcinogenicity. On the basis of the studies described in the 2006 documentation (Hartwig and MAK
Commission 2018) and the studies that have been published since then, it can be concluded that furan is slightly
genotoxic only at toxic doses; genotoxicity is therefore regarded as a secondary effect. Studies are now available
in the low dose range, which yielded negative results. The 13-week gavage studies in rats (Gill et al. 2010) and
mice (Gill et al. 2011) showed that hepatocytes are damaged at lower doses than bile-duct cells (see Section 5.2.2).
Two‐year gavage studies with male F344 rats (FDA 2015; Von Tungeln et al. 2017) and female B6C3F1 mice (Moser
et al. 2009) identified doses at which carcinogenicity was not induced. A NOAEL of 0.092 mg/kg body weight and
day was obtained for furan in rats; subcapsular inflammation was found in the liver of mice at the lowest dose
tested of 0.5 mg/kg body weight. In the 13-week study, the NOAEL for mice was 0.12 mg/kg body weight and day.
As NOAELs are available for mice and rats and a non-genotoxic mechanism of action is considered to be the cause
of carcinogenicity, furan has been re-classified in Carcinogen Category 4 and a MAK value can be established.
Germ cell mutagenicity. In vitro studies found that furan has clastogenic potential. The metabolite
cis-2-butene‑1,4‑dial is mutagenic and clastogenic in vitro, but it is rapidly inactivated in vivo. In vivo furan
induces GC to TA transversions in the cII transgene in the liver and is genotoxic via secondary mechanisms only
at cytotoxic doses that are accompanied by inflammation and cell proliferation. There are no studies available
in germ cells. Toxicity studies revealed lesions of the ovaries and testes only when the animals were exposed to
high doses and had already incurred severe liver damage. Therefore, classification in one of the germ cell mutagen
categories is not required.
MAK value. Low gavage doses of furan induced hepatotoxicity in rats and mice. In F344 rats, inflammation and
apoptosis of hepatocytes were observed in the males at 0.12 mg/kg body weight and day and above after 13 weeks
(Gill et al. 2010), and cholangiofibrosis was found at 0.2 mg/kg body weight and day and above after 2 years (FDA
2015), which was detected only at 2 mg/kg body weight and day and above after 13 weeks. The finding that, at
0.44 mg/kg body weight and day, effects were observed in 30% of the animals after 9 months and in 100% of the
animals after 15 months indicates that the effects increase with the increasing duration of exposure. A NOAEL of
0.092 mg/kg body weight and day was established.
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The inflammation and apoptosis of hepatocytes observed in F344 rats in the 13-week study were not found in
F344 rats in the two‐year study. This may have been caused by genetic differences in F344 strains from different
breeders. Another possible explanation is that these are transient effects that were compensated by the liver after
long-term exposure to furan. However, this is not substantiated by the findings from the two‐year study, which did
not observe apoptosis at the interim examination after 9 months (Beland 2016; FDA 2015). Therefore, inflammation
and apoptosis of the hepatocytes of F344 rats after 13-week administration of furan are used as the basis for the
derivation of the MAK value. The NOAEL for this effect was 0.03 mg/kg body weight and day.
The following toxicokinetic data are used to extrapolate this NOAEL to a concentration in workplace air: the cor-
responding species-specific correction value for the rat determined on the basis of the toxicokinetic data (1:4), the
established oral absorption (100%), the body weight (70 kg) and the respiratory volume (10 m3) of the person, and
the established 90% absorption by inhalation. This results in a concentration in air of 0.06 mg/m3 or 0.021 ml/m3.
An intensification of the effects over time is not taken into account because the effects were not observed in the
chronic study.
A PBPK model shows that after 4‑hour exposure to 10 ml/m3, exposure to the toxic metabolite cis-2-butene‑1,4‑dial
is 3 and 10 times lower in humans than in rats and mice, respectively. The reaction rate is determined by the
transport of furan to the liver rather than its metabolism to form the dialdehyde (Kedderis and Held 1996).Therefore,
interindividual differences in the expression of the enzyme CYP2E1 in humans have no effect on the concentration
of cis-2-butene‑1,4‑dial in the liver. According to these calculations, at the same exposure concentration, the body
burden of furan or its metabolite is lower in humans than in rats or mice. Thus, the margin that is generally
required between the NOAEL from animal studies and the MAK value is not applicable, and a MAK value for furan
of 0.02 ml/m3 has been established.
This low value is far below the MAK value of 2 ml/m3 that was established for the irritant hydrogen chloride. Thus,
in spite of a lack of data, irritation is not assumed to occur after exposure to furan at the MAK value.
As the MAK value was calculated from an oral study and it was found that, unlike after oral administration, in-
halation exposure resulted in lower concentrations in the liver than in the blood (Churchwell et al. 2015), the MAK
value provides additional safety.
Peak limitation. Furan has been classified in Peak Limitation Category II because the MAK value was derived
from a systemic effect. Furan is eliminated rapidly (85% within 24 hours; Hartwig and MAK Commission 2018);
however, the half-life of the reactive metabolite cis-2-butene‑1,4‑dial is not known.Therefore, the default excursion
factor of 2 has been established.
Prenatal toxicity. There are no studies of effects on development. Therefore, furan has been classified in Preg-
nancy Risk Group D.
Absorption through the skin. Studies of the dermal absorption of furan are not available. About 0.5 mg is
absorbed after exposure at the MAK value at a respiratory volume of 10 m3 and 90% absorption by inhalation. On the
basis of model calculations, at least 126 mg is absorbed under the standard conditions of exposure (2000 cm2 surface
area of skin exposed to a saturated aqueous solution for 1 hour). Therefore, dermal absorption may significantly
contribute to the toxicity of furan, and the substance remained being designated with an “H” (for substances which
can be absorbed through the skin in toxicologically relevant amounts).
Sensitization. As clinical findings or results from experimental animal studies are not available for sensitization,
furan has not been designated with “Sh” or “Sa” (for substances which cause sensitization of the skin or airways).
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